Medivation, Inc.
http://www.medivation.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Medivation, Inc.
Finance Watch: Summer Ends, But Fundraising Heats Up For ArsenalBio, Vaxcyte
ArsenalBio closed one of the largest VC rounds so far in 2024, raising $325m in series C funding, while Vaxcyte grossed $1.3bn in a follow-on offering. Also, Circle Pharma closed a $90m series D round and Jazz priced an $850m note sale, but IN8bio revealed a prioritization plan and job cuts.
BioMarin's Agenda Includes $4bn In Sales And Business Development
The company laid out a growth strategy to investors centered on three business units, $4bn in revenue by 2027 and $500m in cost savings.
BioMarin Recruits Amgen R&D’s Friberg, Roche Dealmaker Sabry To Leadership Team
The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.
Ascendis’s Yorvipath Approved By FDA For Hypoparathyroidism But US Launch Delayed
The US launch of Yorvipath will be delayed until Q4 2024 or early 2025 due to manufacturing, though the drug is already available in some European countries.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice